This cellular priming provides the mechanistic foundation for FOXO4-DRI's selective targeting, enabling researchers to eliminate senescent cells without affecting healthy tissue function

Other ingredients Water, centella asiatica extract (12.3%), glycerin, cetyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, glutathione (1,000 ppm), niacinamide (1,000 ppm), madecassic acid, asiaticoside, asiatic acid, solanum melongena (eggplant) fruit extract, melaleuca alternifolia (tea tree) leaf extract, hydrolyzed collagen, beta-glucan, hippophae rhamnoides fruit extract, nelumbo nucifera extract, artemisia annua extract, oryza sativa (rice) extract, saccharomyces ferment, squalane, sodium hyaluronate, dipropylene glycol, butylene glycol, hydrogenated lecithin, cholesterol, xanthan gum, potassium hydroxide, disodium edta, caprylic/capric triglyceride, cyclopentasiloxane, cyclohexasiloxane, saccharide hydrolysate, sorbitan stearate, dimethicone, peg-100 stearate, stearic acid, 1,2-hexanediol, chlorphenesin, carbomer, caprylyl glycol

Furthermore, studies showed an increase in thrombin generation in patients with L-C19 (94), in line with the presence of a hypercoagulable state in these patients
S., Bicca, J., Dos Santos, I